COMPASS Pathways plc (FRA:5Y6)

Germany flag Germany · Delayed Price · Currency is EUR
4.600
-0.320 (-6.50%)
At close: Mar 27, 2026
Market Cap600.93M +101.8%
Revenue (ttm)n/a
Net Income-245.17M
EPS-2.62
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume15
Open4.880
Previous Close4.920
Day's Range4.600 - 4.880
52-Week Range2.100 - 7.650
Betan/a
RSI39.44
Earnings DateMay 7, 2026

About COMPASS Pathways

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Employees 166
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5Y6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements